Biocure Technology (CURE.X.CN) Stock Price

Biocure Technology Price

CSE·CLOSED
0.05
​
Market closed

Biocure Technology stock price

Access this data via the Eulerpool API

Biocure Technology business model & stock analysis

Biocure Technology, Inc. engages in the development and commercialization of biosimilar products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2008-03-27. The firm is engaged in development and commercialization of various biopharmaceutical technologies relating to uses of recombinant and ranibizumab. The firm is comprised of scientists specializing in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. In addition, the Company is developing Biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.

Frequently asked questions about Biocure Technology

Converted at the current exchange rate, the Biocure Technology share trades at 0.03 EUR (0.05 CAD).

The Biocure Technology share (CURE.X.CN) is listed on 3 stock exchanges, including: Frankfurt (1WH.F).

The revenue cannot currently be calculated for Biocure Technology.

The profit cannot currently be calculated for Biocure Technology.

The P/E ratio cannot be calculated for Biocure Technology at the moment.

The P/S cannot be calculated for Biocure Technology currently.

The Eulerpool Quality Score for Biocure Technology is 2/10.

The ISIN of Biocure Technology is CA09075T2065. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biocure Technology is A2JGTL. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biocure Technology is CURE.X.CN. The ticker symbol is used to trade Biocure Technology shares on the stock exchange.

Fair ValueTerminal
0.05 CAD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CAD
Initial public offering
Mar 27, 2008
ISIN
CA09075T2065
Cusip
09075T107
Market capitalization
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.63
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-18.88 %
Gross Margin
—
EBIT Margin
—
Net Margin
—
EPS (Earnings Per Share)
-0.03 CAD
Net Debt / EBIT
-0.09
Debt/Equity
0.04
Last updated Oct 5, 2026, 12:12 PM

Biocure Technology Peer Group

Biocure Technology Ticker

CNQ · CURE.CNFRANKFURT · 1WH.FOTC · BICTF